+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Neuroendocrine Carcinoma"

From
From
Neuroendocrine Tumors Market - Product Thumbnail Image

Neuroendocrine Tumors Market

  • Report
  • January 2025
  • 250 Pages
  • Global
From
Gastric Neuroendocrine Tumors Market - Product Thumbnail Image

Gastric Neuroendocrine Tumors Market

  • Report
  • January 2025
  • 250 Pages
  • Global
From
From
Neuroendocrine Tumor Treatment Market in Canada - Product Thumbnail Image

Neuroendocrine Tumor Treatment Market in Canada

  • Report
  • February 2026
  • 150 Pages
  • Canada
From
Neuroendocrine Tumor Treatment Market in China - Product Thumbnail Image

Neuroendocrine Tumor Treatment Market in China

  • Report
  • February 2026
  • 150 Pages
  • China
From
Neuroendocrine Tumor Treatment Market in Germany - Product Thumbnail Image

Neuroendocrine Tumor Treatment Market in Germany

  • Report
  • February 2026
  • 150 Pages
  • Germany
From
Neuroendocrine Tumor Treatment Market in India - Product Thumbnail Image

Neuroendocrine Tumor Treatment Market in India

  • Report
  • February 2026
  • 150 Pages
  • India
From
Neuroendocrine Tumor Treatment Market in Japan - Product Thumbnail Image

Neuroendocrine Tumor Treatment Market in Japan

  • Report
  • February 2026
  • 150 Pages
  • Japan
From
From
From
From
From
Loading Indicator

Neuroendocrine carcinoma (NEC) is a rare type of cancer that affects the neuroendocrine system, which is responsible for the production of hormones. It is a type of cancer that is often difficult to diagnose and treat. Treatment options for NEC include surgery, chemotherapy, radiation therapy, and targeted therapies. Oncology drugs are used to treat NEC, and they can be used alone or in combination with other treatments. These drugs can help to reduce the size of tumors, slow the growth of cancer cells, and reduce the risk of recurrence. The Neuroendocrine Carcinoma market is a rapidly growing segment of the oncology drugs market. It is driven by the increasing prevalence of NEC, the development of new treatments, and the increasing availability of targeted therapies. Companies in the market include Novartis, Pfizer, Merck, AstraZeneca, and Roche. Show Less Read more